Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences (VTYX)
NASDAQ:VTYX
VTYX Stock Chart & Stats
$13.96
-$0.21(-8.13%)
At close: 4:00 PM EST
$13.96
-$0.21(-8.13%)
Day’s Range― - ―
52-Week Range$0.78 - $25.00
Previous CloseN/A
Volume4.54M
Average Volume (3M)4.15M
Market Cap
$1.00B
Enterprise Value$979.69M
Total Cash (Recent Filing)$192.64M
Total Debt (Recent Filing)$10.02M
Price to Earnings (P/E)―
Beta2.67
Next Earnings
Mar 19, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding71,750,145
10 Day Avg. Volume1,731,531
30 Day Avg. Volume4,154,676
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.59
Price to Sales (P/S)0.00
P/FCF Ratio-1.14
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.62
Forecast
1Y Price Target
$13.38Price Target Upside-4.15% Downside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And Trial OptimizationPositive Phase II signals for the CNS-penetrant candidate and meaningful hsCRP reductions with VTX3232, together with expansion of the VTX2735 trial to international sites and a once-daily formulation, support stronger efficacy signals and improved trial feasibility.
Development And Commercialization CapabilityLilly's scientific, financial, and commercialization resources could enable advancement of Ventyx's programs into larger late-stage trials and more efficient market preparation than Ventyx could achieve independently.
Strategic ValidationEli Lilly's definitive acquisition agreement signals strategic validation of Ventyx's NLRP3 programs and implies these oral inhibitors are viewed as potential best-in-class therapies across cardiometabolic, neurodegenerative, and immunology indications.
Bears Say
Acquisition Execution RiskCompletion of the transaction remains subject to regulatory and stockholder approvals, creating execution risk that the deal may not close as announced.
Operational Capacity And Financing RiskVentyx's limited internal capacity to run large-scale late-stage trials and a relatively constrained cash runway increased the likelihood of pursuing a strategic transaction, highlighting operational and financing vulnerabilities if integration faced delays.
Shareholder Upside LimitationThe announced acquisition establishes a fixed value for Ventyx shares, constraining upside potential for existing shareholders and prompting some analysts to move to neutral or hold ratings.
Ventyx Biosciences News
VTYX FAQ
What was Ventyx Biosciences’s price range in the past 12 months?
Ventyx Biosciences lowest stock price was $0.78 and its highest was $25.00 in the past 12 months.
What is Ventyx Biosciences’s market cap?
Ventyx Biosciences’s market cap is $1.00B.
When is Ventyx Biosciences’s upcoming earnings report date?
Ventyx Biosciences’s upcoming earnings report date is Mar 19, 2026 which is in 43 days.
How were Ventyx Biosciences’s earnings last quarter?
Ventyx Biosciences released its earnings results on Nov 06, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.449 by $0.129.
Is Ventyx Biosciences overvalued?
According to Wall Street analysts Ventyx Biosciences’s price is currently Overvalued.
Does Ventyx Biosciences pay dividends?
Ventyx Biosciences does not currently pay dividends.
What is Ventyx Biosciences’s EPS estimate?
Ventyx Biosciences’s EPS estimate is -0.37.
How many shares outstanding does Ventyx Biosciences have?
Ventyx Biosciences has 71,750,145 shares outstanding.
What happened to Ventyx Biosciences’s price movement after its last earnings report?
Ventyx Biosciences reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.449. Following the earnings report the stock price went down -5.292%.
Which hedge fund is a major shareholder of Ventyx Biosciences?
Currently, no hedge funds are holding shares in VTYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ventyx Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.38 (-4.15% Downside)
$13.38 (-4.15% Downside)
Blogger Sentiment
Bullish
VTYX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
580.48%
12-Months-Change
Fundamentals
Return on Equity
-45.35%
Trailing 12-Months
Asset Growth
-29.77%
Trailing 12-Months
Company Description
Ventyx Biosciences
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
VTYX Stock 12 Month Forecast
Average Price Target
$13.38
▼(-4.15% Downside)
Technical Analysis
Immutep
―
Voyager Therapeutics
―
Silence Therapeutics
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
9.81% Insiders
7.83% Mutual Funds
24.04% Other Institutional Investors
51.58% Public Companies and
Individual Investors